News

JIC Venture Growth Investments, through its JIC Venture Growth Fund 2, has invested in Gaudi Clinical, Inc. (Headquarter: Bunkyo-ku, Tokyo, CEO: Morikuni Tobita; hereinafter referred to as Gaudi Clinical)

‍

Gaudi Clinical is a company to provide cell culture processing service, , collect medical  data, and support regulatory compliance and other related work regulated under the Act on the Safety of Regenerative Medicine (RM Act) (*) in Japan. Its mission is to contribute to improved QOL by providing regenerative medicine such as repairing and improving the function of joint diseased tissues.

‍

Gaudi Clinical’s business is characterized by developing a couple of unique infrastructure. First is an easy movable style of cell adjustment room called “Kiosk”, which originates from the idea of a small open-fronted cubicle selling newspaper and snacks. It is also applicable to cell processing facility. The Kiosk type of cell adjustment room enables to maintain the quality of functions while keeping the installment cost lower. Second is a software to manage the data necessary for hospitals and clinics to comply with the RM Act.

‍

The purpose of this investment is to support the startup originated in Japanese academia, Juntendo University, and extend people’s healthy life expectancy by the spread of regenerative medicine. VGI expects that the society where people can live as long and healthy lives as possible will come true through this investment.

‍

(*) the Act on the Safety of Regenerative Medicine (RM Act) took effect on November 25th, 2014 with an aim to provide regenerative medicine quickly and safely. It clarifies the measures necessary for ensuring patient safety and regulates regenerative medical technologies using processed cells for ensuring the safety and scientific validity.

‍

_{The information contained in this notice is current at the time of publication and subject to change without notice.}